EICHOR
● Active Not Recruiting
Premedication to Reduce Amivantamab Associated Infusion Related Reactions
Condition: Carcinoma, Non-Small-Cell Lung · Sponsor: Janssen Research & Development, LLC
About this study
The purpose of the study is to separately assess the potential of dexamethasone, montelukast and methotrexate administration, prior to amivantamab infusion given through a needle in the vein, to decrease the incidence and/or severity of first-dose infusion related reactions.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (36)
| Compassionate Cancer Care | Fountain Valley, California, United States | — |
| Virginia Cancer Specialists | Fairfax, Virginia, United States | — |
| UW Medicine Valley Medical Center | Renton, Washington, United States | — |
| CHU de Brest - Hopital de la Cavale Blanche | Brest, France | — |
| Centre Leon Berard | Lyon, France | — |
| Hopital Cochin | Paris, France | — |
| Hopital Europeen Georges-Pompidou | Paris, France | — |
| CHU Rouen Hopital Charles Nicolle | Rouen, France | — |
| Nouvel Hopital Civil - CHU Strasbourg | Strasbourg, France | — |
| Chungbuk National University Hospital | Cheongju-si, South Korea | — |
| National Cancer Center | Gyeonggi-do, South Korea | — |
| Gachon University Gil Medical Center | Incheon, South Korea | — |
+ 24 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.